#ACR BEST Abstracts from San Diego – Day 1 Save

Jack Cush, MD

Nov 13, 2023 10:15 am

The RheumNow faculty reporters have been scouring the meeting for what they believe to be the best presentations from the first day at ACR 2023 in San Diego. From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from Sunday Nov. 12th. You can spot these on Twitter by looking for the (#ACRbest) hashtag.

Important plenary re:reduced vs standard GC for AAV... IRL

PEXIVAS & recent guidelines supported low dose taper

Real world data w/severe dx? Increased risk of death & ESKD for REDUCED pts

Need full data but yikes... @RheumNow #ACR23 #ACRBest pic.twitter.com/3S23O9d1ok
— Mike Putman (@EBRheum) November 12, 2023

ABS0524:

⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) flares among high risk pts w/ axSpA
➡️active dz, HLAB27+, 2 or more AAU flares

⭐️CZP reduced AAU flare rate by 87%#ACR23 @RheumNow #ACRBest pic.twitter.com/rW0N18agMO
— Meral K. El Ramahi, MD (@MeralElRamahiMD) November 13, 2023

Interesting study on PEXIVAS reduced steroid use from today's plenary session!
Reduced steroid dose in GPA/MPA pts associated w/
INCREASED risk of death, ESKD, progression of dz
Even greater risk in pts with higher Cr lvls or RTX induction use@RheumNow #ACR23 Abs#0725 #ACRbest pic.twitter.com/frsOrANKhf
— Robert B Chao, MD (@doctorRBC) November 12, 2023

Abst#0725 #ACR23 @RheumNow
PEXIVAS Real life data!
GPA & MPA pts - Retrosp observ study
⭐️Reduced-dose GC regimen ass w/ INCREASED risk of death, ESKD, progression
Greatest risk: pt w Cr levels >300 umol/L, RTX induction Rx
⚠️Caution w/ reduced GC, RTX, severe kidney dis#ACRBest pic.twitter.com/7qI5c1ZiqO
— Eric Dein (@ericdeinmd) November 12, 2023

Results of this study by Dr Fava show that most urinary BMs of histological activity were⬆️at 6 & 12mos in pts who lost GFR at 3yrs.
☝️Some LN pts still develop renal damage despite clinical response. Is there a role for BMs in monitoring tx? #ACR23 ABST0850 @RheumNow #ACRbest pic.twitter.com/H5G6LJ22lw
— sheila (@RHEUMarampa) November 13, 2023

Urinary biomarkers precede loss of kidney fxn in LN by @andreafava #Ab0850 @RheumNow #ACR23
73 pts w LN. 44% devel GFR loss
Elevation of urinary biomark of histo activity at 6, 12 mo predict GFR loss at 3 yrs - esp IL-16, >> proteinuria
Combo biomark 12 mo: AUC 0.95#ACRBest pic.twitter.com/M7sfpCm7Kz
— Eric Dein (@ericdeinmd) November 13, 2023

#ACR23 Abstr#0781 Pooled analyses of #lupus nephritis patients in the SOC arm (MMF or Cyclo) in 4 RCTs showed after IV MEP, no significant efficacy difference in renal response but few adverse events favouring low dose steroid (up to 5mg/kg/d) vs high dose @RheumNowNews #ACRBest pic.twitter.com/CoOc9LwHML
— Md Yuzaiful Md Yusof (@Yuz6Yusof) November 12, 2023

You should not tire of hearing this! Phase2 RCT of #dazodalibep -CD40L antagonist for #extra glandular & could also have #glandular problems in #Sjogrens was + improving Facit #fatigue & ESSPRI, etc. #GameChanger #ACR23 #ACRbest ⁦@ACRheum⁩ ⁦@RheumNow⁩ Pos#L10 pic.twitter.com/DfChrAyslL
— Janet Pope (@Janetbirdope) November 12, 2023

EISER study: Undiagnosed IBD in SpA
Abs#0495 #ACR23 @RheumNow
559 pts, 47% PsA/53% SpA (80% r-AxSpA)
Higher mean fecal calprotectin in r-AxSpA (395 vs 305 nrAxSpA/PsA)
14.6% IBD symptoms, 23 patients (4.4% were dx w IBD)
Fecal calprotectin & history can uncover IBD#ACRBest
— Eric Dein (@ericdeinmd) November 12, 2023

Should the cost of #CAR-T stop us from considering in severe refractory #lupus? So far update of German group show remission - drug free and great safety. But hold on..we need RCTs with an active control and longer f/u, but I am impressed! #ACR23 #ACRbest @ACRheum @RheumNow #784 pic.twitter.com/mRMWLCbpCY
— Janet Pope (@Janetbirdope) November 12, 2023

APIPPRA trial of abatacept to prevent RA in sero+ arthralgia. Picture paints a thousand words - big difference at week 52 (on abatacept) and watch those lines converge Abstr#0835 #ACR23 #ACRbest @RheumNow https://t.co/cwX389TUZN pic.twitter.com/2CQHYlW0nq
— Richard Conway (@RichardPAConway) November 13, 2023

Risk factor for 1st Thrombosis in OB APS
Ab#0115 #ACR23 @RheumNow
186 OAPS pts, followed mean 5.4 yrs. 11 thrombotic events
Risk factors: Triple pos APS Abs (OR 11.6), hypocomplementemia (OR 9)
Low dose Aspirin (OR 0.14), HCQ (OR 0.11) reduced thrombosis#ACRBest pic.twitter.com/y4KaEAZzA7
— Eric Dein (@ericdeinmd) November 12, 2023

Phase 2 RCT of TLL-018 (JAK1/TYK2i) vs Tofa in RA. 101 patients. ACR50 72% vs 42%. 83% of tofa-IR achieved ACR50 on TLL-018. Can't wait for the phase 3 data! Abstr#0840 #ACR23 @RheumNow #ACRbest https://t.co/wjGx4Edxyb pic.twitter.com/n6CL8G01Wo
— Richard Conway (@RichardPAConway) November 13, 2023